Literature DB >> 28383760

Nephrogenic rests in Wilms tumors treated with preoperative chemotherapy: The UK SIOP Wilms Tumor 2001 Trial experience.

Gordan M Vujanić1, John R Apps2, Veronica Moroz3, Federica Ceroni2, Richard D Williams2, Neil J Sebire4, Kathy Pritchard-Jones2.   

Abstract

BACKGROUND: Nephrogenic rests (NRs) are abnormally persistent foci of embryonal cells, thought to be the precursor lesion of Wilms tumors (WTs). To date, their presence has not been systematically examined in WTs treated with preoperative chemotherapy.
METHODS: A systematic analysis of the data on NRs in WTs treated with preoperative chemotherapy obtained from the UK cohort of the International Society of Pediatric Oncology (SIOP) WT 2001 Trial. The study was based on central pathology review of full sets of slides from pathological specimens, with a median of 28 slides reviewed per case.
RESULTS: NRs were identified in 40% of unilateral WTs, including 25% perilobar nephrogenic rest (PLNR), 9% intralobar nephrogenic rest (ILNR), 5% both PLNR and ILNR, and 1% nephroblastomatosis, and in 93% of cases with bilateral lesions. ILNRs were associated with stromal histology and a younger age at diagnosis and found frequently in patients with congenital anomalies associated with WT1 mutation. PLNRs were found frequently in patients with overgrowth syndromes.
CONCLUSIONS: The prevalence of NRs in WTs after preoperative chemotherapy observed in SIOP UK WT 2001 Trial is similar to the previously published data on NRs not treated with preoperative chemotherapy. Their epidemiology supports at least two pathways to Wilms tumorigenesis.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Wilms tumor; nephrogenic rests; preoperative chemotherapy

Mesh:

Substances:

Year:  2017        PMID: 28383760     DOI: 10.1002/pbc.26547

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

1.  Botryoid Wilms tumor: a non-existent "entity" causing diagnostic and staging difficulties.

Authors:  Gordan M Vujanić; Marco Schiavo Lena; Neil J Sebire
Journal:  Virchows Arch       Date:  2018-12-04       Impact factor: 4.064

2.  Revisiting Wilms tumour surveillance in Beckwith-Wiedemann syndrome with IC2 methylation loss, reply.

Authors:  Frédéric Brioude; Raoul Hennekam; Jet Bliek; Carole Coze; Thomas Eggermann; Giovanni B Ferrero; Christian Kratz; Yves Le Bouc; Saskia M Maas; Deborah J G Mackay; Eamonn R Maher; Alessandro Mussa; Irene Netchine
Journal:  Eur J Hum Genet       Date:  2018-02-15       Impact factor: 4.246

3.  Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis.

Authors:  Michael V Ortiz; Shannon Fernandez-Ledon; Kavitha Ramaswamy; Christopher J Forlenza; Neerav N Shukla; Rachel Kobos; Todd E Heaton; Michael P LaQuaglia; Peter G Steinherz
Journal:  Pediatr Blood Cancer       Date:  2018-10-18       Impact factor: 3.167

4.  The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol.

Authors:  Gordan M Vujanić; Manfred Gessler; Ariadne H A G Ooms; Paola Collini; Aurore Coulomb-l'Hermine; Ellen D'Hooghe; Ronald R de Krijger; Daniela Perotti; Kathy Pritchard-Jones; Christian Vokuhl; Marry M van den Heuvel-Eibrink; Norbert Graf
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

Review 5.  Bilateral Wilms Tumor: A Surgical Perspective.

Authors:  Andrew J Murphy; Andrew M Davidoff
Journal:  Children (Basel)       Date:  2018-09-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.